Skip to content

Development and Validation of an Alfentanil-Centered Precision Analgesia Pathway for Perioperative Management in Thoracic Day Surgery: A Multicenter Randomized Controlled Trial

Development and Validation of an Alfentanil-Centered Precision Analgesia Pathway for Perioperative Management in Thoracic Day Surgery: A Multicenter Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127474
Enrollment
Unknown
Registered
2026-07-01
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nodules (possible early lung cancer), benign lung tumors, pulmonary bullae, spontaneous pneumothorax, which may be accompanied by chest tightness, chest pain, cough, or be asymptomatic

Interventions

Alfentanil Group:Anesthesia induction was performed using alfentanil (15 µg/kg), and alfentanil (0.5-1.0 µg/kg/min) was continuously infused during the operation for maintenance, with precise titratio
Sufentanil Group:Anesthesia induction was performed using sufentanil (0.2 µg/kg), and sufentanil (0.15 µg/kg) was added as needed during the operation.

Sponsors

The First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing thoracic day surgery; 2. 18 years <= age <= 70 years; 3. 18 kg/m^2 <= BMI <= 28 kg/m^2; 4. American Society of Anesthesiologists (ASA) physical status grade I-II; 5. No severe cardiopulmonary disease, hepatic or renal dysfunction, or other major diseases.

Exclusion criteria

Exclusion criteria: 1.Recent (within 2 weeks) respiratory tract infection; 2.Pregnant or breastfeeding women; 3.History of poorly controlled chronic respiratory diseases (e.g., asthma, chronic bronchitis, chronic obstructive pulmonary disease); 4.Known allergy or contraindication to the study drugs; 5.Cognitive or communication impairments that preclude completion of questionnaire assessments;

Design outcomes

Primary

MeasureTime frame
24-hour resting pain Numerical Rating Scale score;24-hour Quality of Recovery-15 total score;

Secondary

MeasureTime frame
Incidence of opioid-related adverse events;Incidence of chronic post-surgical pain at 3 months;Extubation time;Days alive and at home within 30 days postoperatively;48-hour QoR-15 total score;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactYuan Liuqing

The First Affiliated Hospital of Gannan Medical University

573738165@qq.com+86 797 8689062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026